Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2551

Sort by

Sort Order Select

Journal Articles

Placental HTRA1 cleaves α 1 -antitrypsin to generate a NET-inhibitory peptide

Robert A. Campbell, Heather D. Campbell, J. Samuel Bircher, Claudia Valeria de Araujo, Frederik Denorme, Jacob L. Crandell, John L. Rustad, Josh Monts, Mark J. Cody, Yasuhiro Kosaka, Christian C. Yost

Blood (2021) 138 (11): 977–988.

https://doi.org/10.1182/blood.2020009021

Published: 2021

Includes: Supplemental data

Journal Articles

Pediatric hemophagocytic lymphohistiocytosis

Scott W. Canna, Rebecca A. Marsh

Blood (2020) 135 (16): 1332–1343.

https://doi.org/10.1182/blood.2019000936

Published: 2020

Journal Articles

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Blood (2019) 134 (Supplement_1): 579.

https://doi.org/10.1182/blood-2019-124953

Published: 2019

Journal Articles

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Haris Ali, MD, David Snyder, MD, Tracy Stiller, MS, Timothy Synold, PhD, Saloomeh Mokhtari, Joycelynne Palmer, PhD, Amandeep Salhotra, MD, Vinod A. Pullarkat, MD, Ji-lian Cai, MD, Stephen J Forman, MD, Matthew Mei, MD, Ryotaro Nakamura, MD

Blood (2019) 134 (Supplement_1): 669.

https://doi.org/10.1182/blood-2019-127445

Published: 2019

Journal Articles

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Jorge E. Cortes, MD, Eunice S. Wang, MD, Justin M. Watts, MD, Sangmin Lee, MD, Maria R. Baer, MD, Kim-Hien Dao, DO, PhD, Shira Dinner, MD, Jay Yang, MD, William B. Donnellan, MD, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Christian Recher, MD PhD, Patrick Kelly, MD, Jennifer Sweeney, Julie Brevard, Patrick Henrick, Sanjeev Forsyth, Sylvie Guichard, Hesham Mohamed, MD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 674.

https://doi.org/10.1182/blood-2019-124360

Published: 2019

Journal Articles

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

David Gottlieb, MBBS, MD FRACP, FRCPA, Wei Jiang, MBBS, BSc, BA, Selmir Avdic, PhD, Leighton Clancy, BSc PhD, Gaurav Sutrave, MBBS, Caroline M Bateman, PhDMBBS,FRACP,FRCPath,MRCP, Elissa Atkins, RN, Adrian Gabriel Selim, MBBS, Vicki Antonenas, BSc, David Collins, RN BSc (HONS) MN MapptMgt, Janine Street, BSc MSc (Hons), Renee Simms, BSc, Peter J. Shaw, MA,FRACP, David Ritchie, MD PhD, Emily Blyth, B. MDHons), FRACP, FRCPA, PhD

Blood (2019) 134 (Supplement_1): 251.

https://doi.org/10.1182/blood-2019-125166

Published: 2019

Journal Articles

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Colleen Annesley, MD, Rebecca Gardner, MD, Ashley Wilson, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Qian Vicky Wu, PhD, Adam Brand, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2019) 134 (Supplement_1): 223.

https://doi.org/10.1182/blood-2019-131346

Published: 2019

Journal Articles

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Marek Trněný, MD, John P. Leonard, MD, Huilai Zhang, MD, Grzegorz Nowakowski, MD, Koji Izutsu, MD PhD, Nathan H. Fowler, MD, Catherine Thieblemont, MD PhD, Pier Luigi Zinzani, MD PhD, Stacey Kalambakas, MD, Myron Czuczman, Pierre Fustier, PhD, Chengqing Wu, PhD, John G. Gribben, MD DSc

Blood (2019) 134 (Supplement_1): 347.

https://doi.org/10.1182/blood-2019-122461

Published: 2019

Journal Articles

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Blood (2019) 134 (Supplement_1): 357.

https://doi.org/10.1182/blood-2019-131939

Published: 2019

Journal Articles

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Jessica A. Pollard, MD, Todd A. Alonzo, PhD, Patrick A. Brown, MD, Robert B. Gerbing, Elizabeth Fox, MD, John Kim Choi, MD, Brian T. Fisher, DO, MSCE, Betsy A Hirsch, PhD, Samir Kahwash, MD, John E. Levine, MDMS, Michael R. Loken, PhD, Susana C. Raimondi, PhD, Katherine Tarlock, MD, Andrew C. Wood, MBCHB, Lillian Sung, MD PhD, Anders E. Kolb, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Richard Aplenc, MD PhD

Blood (2019) 134 (Supplement_1): 292.

https://doi.org/10.1182/blood-2019-129557

Published: 2019

Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 237.

https://doi.org/10.1182/blood-2019-124866

Published: 2019

Journal Articles

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Mikkael A. Sekeres, MD MS, Michael W. Schuster, MD, Magalie Joris, MD, Jürgen Krauter, MD, Johan A. Maertens, MD PhD, Emmanuel Gyan, MD PhD, Tibor Kovacsovics, MD, Amit Verma, MBBS, Paresh Vyas, MD PhD, Eunice S. Wang, MD, Weidong Wendy Ma, Mirjana Zeremski, MD, Arthur Kudla, Geoffrey Chan, MD, Amer M. Zeidan, MBBS, MHS

Blood (2019) 134 (Supplement_1): 177.

https://doi.org/10.1182/blood-2019-124050

Published: 2019

Journal Articles

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Alex F. Herrera, MD, Robert W. Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, Matthew Mei, MD, Leslie L. Popplewell, MD FRCPA, Auayporn P. Nademanee, MDBS, Liana Nikolaenko, MD, Kathryn McBride, Ricardo Ortega, Joo Y. Song, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Stephen J Forman, MD, Hun Ju Lee, MD

Blood (2019) 134 (Supplement_1): 239.

https://doi.org/10.1182/blood-2019-123162

Published: 2019

Journal Articles

Levofloxacin Prophylaxis Is Effective and Cost-Effective in Pediatric Patients with Acute Myeloid Leukemia

Meghan McCormick, MD, Erika Friehling, MD, Ram Kalpatthi, MD, Ken Smith, MD MS

Blood (2019) 134 (Supplement_1): 335.

https://doi.org/10.1182/blood-2019-122071

Published: 2019

Journal Articles

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Javier Munoz, MD, Samantha Jaglowski, MDMPH, Matthew S. McKinney, MD, Iris Isufi, MD, Patrick J. Stiff, MD, Jessica Sachs, MD, Ann Ranger, PhD, Patricia Harris, MPH, Francis Payumo, BSc, MSc, Luke P. Akard, MD

Blood (2019) 134 (Supplement_1): 244.

https://doi.org/10.1182/blood-2019-123810

Published: 2019

Journal Articles

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie Johnson, MD, Pauline Brice, John Radford, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, MD PhD, Bastian Von Tresckow, Margaret A. Shipp, MD, Alex F. Herrera, MD, Jianxin Lin, Eunhee Kim, Mohammed Farooqui, Patricia Marinello, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 240.

https://doi.org/10.1182/blood-2019-127280

Published: 2019

Journal Articles

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Kirit M. Ardeshna, MBBChir, Maria A V Marzolini, Jane Norman, MD, Muhammad Al-Hajj, Simon Thomas, PhD, Jim Faulkner, Ekaterini Kotsopoulou, Martin Pule, MD, Vijay G R Peddareddigari, Nushmia Z Khokhar, Maud Jonnaert, PhD, Robert Chen, MD, Wendy Osborne, MD

Blood (2019) 134 (Supplement_1): 246.

https://doi.org/10.1182/blood-2019-122724

Published: 2019

Journal Articles

Invasive Fungal Diseases Caused By Rare Pathogens in Large Cohort of Pediatric and Adult Patients after Hematopoietic Stem Cell Transplantation and Chemotherapy

Blood (2019) 134 (Supplement_1): 4497.

https://doi.org/10.1182/blood-2019-127961

Published: 2019

Journal Articles

Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation

Maria Stamouli, Ioannis Tsonis, MD, Konstantinos Gkirkas, Christina Economopoulou, Thomas Thomopoulos, MD, Anna Paisiou, MD, Nikolaos Siafakas, Spyridon Pournaras, Anastasia Antoniadou, Aggeliki Karagiannidi, Joseph Meletiadis, Dimitra Kavatha, George Vassilopoulos, MD PhD, Stavros Gigantes, MD, Ioannis Baltadakis, MD, Evgenios Goussetis, Dimitrios Karakasis, MD, Panagiotis Tsirigotis

Blood (2019) 134 (Supplement_1): 4498.

https://doi.org/10.1182/blood-2019-128362

Published: 2019

Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Blood (2019) 134 (Supplement_1): 4319.

https://doi.org/10.1182/blood-2019-123331

Published: 2019

NARROW

Placental HTRA1 cleaves α 1 -antitrypsin to generate a NET-inhibitory peptide

Pediatric hemophagocytic lymphohistiocytosis

Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Peri-Transplant Administration of Ruxolitinib Is Safe and Feasible in Patients with Myelofibrosis: Primary Results of a Pilot Open-Label Study of Ruxolitinib Administration in Combination with Reduced Intensity Conditioning

Olutasidenib (FT-2102) Induces Rapid Remissions in Patients with IDH1-Mutant Myelodysplastic Syndrome: Results of Phase 1/2 Single Agent Treatment and Combination with Azacitidine

Administration of Third-Party Virus-Specific T-Cells (VST) at the Time of Initial Therapy for Infection after Haemopoietic Stem Cell Transplant Is Safe and Associated with Favourable Clinical Outcomes (the R3ACT-Quickly trial)

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Subgroup Analyses of Elderly Patients Aged ≥ 70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R 2 ) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for First-Line Treatment of IGHV -Mutated CLL and without Del(17p)/Mutated TP53

Sorafenib in Combination with Standard Chemotherapy for Children with High Allelic Ratio FLT3/ITD+ AML Improves Event-Free Survival and Reduces Relapse Risk: A Report from the Children's Oncology Group Protocol AAML1031

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

PET-Adapted Nivolumab or Nivolumab Plus ICE As First Salvage Therapy in Relapsed or Refractory Hodgkin Lymphoma

Levofloxacin Prophylaxis Is Effective and Cost-Effective in Pediatric Patients with Acute Myeloid Leukemia

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Phase 1/2 Study of AUTO3 the First Bicistronic Chimeric Antigen Receptor (CAR) Targeting CD19 and CD22 Followed By an Anti-PD1 in Patients with Relapsed/Refractory (r/r) Diffuse Large B Cell Lymphoma (DLBCL): Results of Cohort 1 and 2 of the Alexander Study

Invasive Fungal Diseases Caused By Rare Pathogens in Large Cohort of Pediatric and Adult Patients after Hematopoietic Stem Cell Transplantation and Chemotherapy

Oral Ribavirin with or without the Addition of Immune Globulin for the Treatment of Lower Respiratory Tract Infections Due to Respiratory Syncytial Virus or Parainfluenza in Patients after Allogeneic Stem Cell Transplantation

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only